REFERENCES
1. Rzany B, Hilton S, Prager W, et al. Expert guideline on the use of porcine collagen in aesthetic medicine. J Dtsch Dermatol Ges 2010;8:210-7.
2. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol 2013;6:295-316.
3. Plastic surgery statistics report 2020. Available from: https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf. [Last accessed on 14 Aug 2023].
4. Mehta P, Kaplan JB, Zhang-nunes S. Ischemic complications of dermal fillers. Plast Aesthet Res 2022;9:57.
5. Alam M, Dover JS. Management of complications and sequelae with temporary injectable fillers. Plast Reconstr Surg 2007;120:98S-105S.
6. Shah NS, Lazarus MC, Bugdodel R, et al. The effects of topical vitamin K on bruising after laser treatment. J Am Acad Dermatol 2002;47:241-4.
7. Cohen JL, Bhatia AC. The role of topical vitamin K oxide gel in the resolution of postprocedural purpura. J Drugs Dermatol 2009;8:1020-4.
8. Kovács RK, Bodai L, Dobozy A, Kemény L. Lack of the effect of topical vitamin K on bruising after mechanical injury. J Am Acad Dermatol 2004;50:982-3.
9. Tao JP, Aakalu VK, Freitag SK, et al. Homeopathic agents or vitamins in reducing ecchymosis after oculofacial surgery: a report by the american academy of ophthalmology. Ophthalmology 2022;129:220-6.
10. Goodman GJ, Liew S, Callan P, Hart S. Facial aesthetic injections in clinical practice: pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. Australas J Dermatol 2020;61:217-25.
11. de Boulle K, Heydenrych I. Patient factors influencing dermal filler complications: prevention, assessment, and treatment. Clin Cosmet Investig Dermatol 2015;8:205-14.
12. Chiang YZ, Pierone G, Al-Niaimi F. Dermal fillers: pathophysiology, prevention and treatment of complications. J Eur Acad Dermatol Venereol 2017;31:405-13.
13. Kassir M, Gupta M, Galadari H, et al. Complications of botulinum toxin and fillers: a narrative review. J Cosmet Dermatol 2020;19:570-3.
14. Fulton J, Caperton C, Weinkle S, Dewandre L. Filler injections with the blunt-tip microcannula. J Drugs Dermatol 2012;11:1098-103.
15. Beer KR. Safety and effectiveness of injection of calcium hydroxylapatite via blunt cannula compared to injection by needle for correction of nasolabial folds. J Cosmet Dermatol 2014;13:288-96.
16. Urdiales-Gálvez F, Delgado NE, Figueiredo V, et al. Treatment of soft tissue filler complications: expert consensus recommendations. Aesthetic Plast Surg 2018;42:498-510.
17. Sadeghpour M, Quatrano NA, Bonati LM, Arndt KA, Dover JS, Kaminer MS. Delayed-onset nodules to differentially crosslinked hyaluronic acids: comparative incidence and risk assessment. Dermatol Surg 2019;45:1085-94.
18. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg 2006;118:92S-107S.
19. Goldberg RA, Fiaschetti D. Filling the periorbital hollows with hyaluronic acid gel: initial experience with 244 injections. Ophthalmic Plast Reconstr Surg 2006;22:335-41; discussion 341-3.
20. Kpodzo DS, Nahai F, McCord CD. Malar mounds and festoons: review of current management. Aesthet Surg J 2014;34:235-48.
21. Mustak H, Fiaschetti D, Goldberg RA. Filling the periorbital hollows with hyaluronic acid gel: long-term review of outcomes and complications. J Cosmet Dermatol 2018;17:611-6.
22. Funt DK. Avoiding malar edema during midface/cheek augmentation with dermal fillers. J Clin Aesthet Dermatol 2011;4:32-6.
23. Pessa JE, Garza JR. The malar septum: the anatomic basis of malar mounds and malar edema. Aesthet Surg J 1997;17:11-7.
24. Pessa JE, Zadoo VP, Adrian EK, Woodwards R, Garza JR. Anatomy of a “black eye”: a newly described fascial system of the lower eyelid. Clin Anat 1998;11:157-61.
25. Mendelson BC, Muzaffar AR, Adams WP Jr. Surgical anatomy of the midcheek and malar mounds. Plast Reconstr Surg 2002;110:885-96; discussion 897-911.
26. Newberry CI, Mccrary H, Thomas JR, Cerrati EW. Updated management of malar edema, mounds, and festoons: a systematic review. Aesthet Surg J 2020;40:246-58.
27. Alghoul M, Codner MA. Retaining ligaments of the face: review of anatomy and clinical applications. Aesthet Surg J 2013;33:769-82.
28. Griepentrog GJ, Lucarelli MJ, Burkat CN, Lemke BN, Rose Jr JG. Periorbital edema following hyaluronic acid gel injection: a retrospective review. Am J Cosmet Surg 2011;28:251-4.
29. Zoumalan CI. Managing periocular filler-related syndrome prior to lower blepharoplasty. Aesthetic Plast Surg 2019;43:115-22.
30. Iverson SM, Patel RM. Dermal filler-associated malar edema: treatment of a persistent adverse effect. Orbit 2017;36:473-5.
32. Glass GE, Tzafetta K. Optimising treatment of Bell's Palsy in primary care: the need for early appropriate referral. Br J Gen Pract 2014;64:e807-9.
33. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007;357:1598-607.
34. McAllister DA, Liu L, Shi T, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Health 2019;7:e47-57.
35. Chen N, Zhou M, He L, Zhou D, Li N. Acupuncture for Bell's palsy. Cochrane Database Syst Rev 2010;2010:CD002914.
36. Cardoso JR, Teixeira EC, Moreira MD, Fávero FM, Fontes SV, Bulle de Oliveira AS. Effects of exercises on Bell's palsy: systematic review of randomized controlled trials. Otol Neurotol 2008;29:557-60.
37. Rootman DB, Lin JL, Goldberg R. Does the tyndall effect describe the blue hue periodically observed in subdermal hyaluronic acid gel placement? Ophthalmic Plast Reconstr Surg 2014;30:524-7.
38. Philipp-Dormston WG, Goodman GJ, De Boulle K, et al. Global approaches to the prevention and management of delayed-onset adverse reactions with hyaluronic acid-based fillers. Plast Reconstr Surg Glob Open 2020;8:e2730.
39. Philipp-Dormston WG, Bergfeld D, Sommer BM, et al. Consensus statement on prevention and management of adverse effects following rejuvenation procedures with hyaluronic acid-based fillers. J Eur Acad Dermatol Venereol 2017;31:1088-95.
40. Fitzgerald R, Bertucci V, Sykes JM, Duplechain JK. Adverse reactions to injectable fillers. Facial Plast Surg 2016;32:532-55.
41. Rayess HM, Svider PF, Hanba C, et al. A cross-sectional analysis of adverse events and litigation for injectable fillers. JAMA Facial Plast Surg 2018;20:207-14.
42. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg 2009;35 Suppl 2:1672-80.
44. Rzany B, Becker-Wegerich P, Bachmann F, Erdmann R, Wollina U. Hyaluronidase in the correction of hyaluronic acid-based fillers: a review and a recommendation for use. J Cosmet Dermatol 2009;8:317-23.
45. Schnabel D, Esposito DH, Gaines J, et al. RGM Outbreak Investigation Team. Multistate US outbreak of rapidly growing mycobacterial infections associated with medical tourism to the Dominican Republic, 2013-2014(1). Emerg Infect Dis 2016;22:1340-7.
46. Kim JSTW, Dos Santos Guadanhim LR, De Barros Nunes GJ, Dias Da Rocha MA, Munia MA, Yarak S. Herpes zoster as a differential diagnosis for ischemia after facial hyaluronic acid filler. J Clin Aesthet Dermatol 2020;13:29-31.
47. Wang C, Sun T, Yu N, Wang X. Herpes reactivation after the injection of hyaluronic acid dermal filler: a case report and review of literature. Medicine 2020;99:e20394.
48. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008;168:1137-44.
50. Beleznay K, Carruthers JD, Carruthers A, Mummert ME, Humphrey S. Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management. Dermatol Surg 2015;41:929-39.
51. Convery C, Davies E, Murray G, Walker L. Delayed-onset nodules (DONs) and considering their treatment following use of hyaluronic acid (HA) fillers. J Clin Aesthet Dermatol 2021;14:E59-E67.
52. Arron ST, Neuhaus IM. Persistent delayed-type hypersensitivity reaction to injectable non-animal-stabilized hyaluronic acid. J Cosmet Dermatol 2007;6:167-71.
53. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. J Eur Acad Dermatol Venereol 2008;22:150-61.
54. Alijotas-Reig J, Fernández-Figueras MT, Puig L. Late-onset inflammatory adverse reactions related to soft tissue filler injections. Clin Rev Allergy Immunol 2013;45:97-108.
55. Munavalli GG, Guthridge R, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment”. Arch Dermatol Res 2022;314:1-15.
56. Decates T, Kadouch J, Velthuis P, Rustemeyer T. Immediate nor delayed type hypersensitivity plays a role in late inflammatory reactions after hyaluronic acid filler injections. Clin Cosmet Investig Dermatol 2021;14:581-9.
57. Turkmani MG, De Boulle K, Philipp-Dormston WG. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. Clin Cosmet Investig Dermatol 2019;12:277-83.
58. Rzany B, DeLorenzi C. Understanding, avoiding, and managing severe filler complications. Plast Reconstr Surg 2015;136:196S-203S.
59. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. a clinical and histological study. Dermatol Surg 1998;24:1317-25.
61. Ledon JA, Savas JA, Yang S, Franca K, Camacho I, Nouri K. Inflammatory nodules following soft tissue filler use: a review of causative agents, pathology and treatment options. Am J Clin Dermatol 2013;14:401-11.
62. Modarressi A, Nizet C, Lombardi T. Granulomas and nongranulomatous nodules after filler injection: different complications require different treatments. J Plast Reconstr Aesthet Surg 2020;73:2010-5.
63. Lemperle G, Gauthier-Hazan N, Wolters M, Eisemann-Klein M, Zimmermann U, Duffy DM. Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes. Plast Reconstr Surg 2009;123:1842-63.
64. Rohrich RJ, Monheit G, Nguyen AT, Brown SA, Fagien S. Soft-tissue filler complications: the important role of biofilms. Plast Reconstr Surg 2010;125:1250-6.
65. Gottfried L. No proof that biofilm bacteria are causing dermal filler granulomas. Am J Biomed Sci & Res 2019;4:17-22.
66. Alcântara CEP, Noronha MS, Cunha JF, Flores IL, Mesquita RA. Granulomatous reaction to hyaluronic acid filler material in oral and perioral region: A case report and review of literature. J Cosmet Dermatol 2018;17:578-83.
67. Lemperle G, Gauthier-Hazan N. Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options. Plast Reconstr Surg 2009;123:1864-73.
68. Wolfram D, Tzankov A, Piza-Katzer H. Surgery for foreign body reactions due to injectable fillers. Dermatology 2006;213:300-4.
69. Jang JW, Kang SY. Evaluation and management of facial granuloma caused by various injection materials. Arch Craniofac Surg 2021;22:26-32.
70. Broly M, Marie J, Picard C, et al. Management of granulomatous foreign body reaction to fillers with methotrexate. J Eur Acad Dermatol Venereol 2020;34:817-20.
71. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002;28:491-4.
72. Artzi O, Loizides C, Verner I, Landau M. Resistant and recurrent late reaction to hyaluronic acid-based gel. Dermatol Surg 2016;42:31-7.
73. Owczarczyk-Saczonek A, Zdanowska N, Wygonowska E, Placek W. The immunogenicity of hyaluronic fillers and its consequences. Clin Cosmet Investig Dermatol 2021;14:921-34.
74. Baeva LF, Lyle DB, Rios M, Langone JJ, Lightfoote MM. Different molecular weight hyaluronic acid effects on human macrophage interleukin 1β production. J Biomed Mater Res A 2014;102:305-14.
75. Bhojani-Lynch T. Late-onset inflammatory response to hyaluronic acid dermal fillers. Plast Reconstr Surg Glob Open 2017;5:e1532.
76. Lee JM, Kim YJ. Foreign body granulomas after the use of dermal fillers: pathophysiology, clinical appearance, histologic features, and treatment. Arch Plast Surg 2015;42:232-9.
77. Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep 2021;10:63-8.
78. Michon A. ACE inhibitors-an effective treatment for hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination. J Cosmet Dermatol 2022;21:1369-70.
79. Rauso R, Lo Giudice G, Zerbinati N, Nicoletti GF, Fragola R, Tartaro G. Adverse events following COVID-19 vaccine in patients previously injected with facial filler: scoping review and case report. Appl Sci 2021;11:10888.
80. Dayan SH, Arkins JP, Brindise R. Soft tissue fillers and biofilms. Facial Plast Surg 2011;27:23-8.
81. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-93.
82. Monheit GD, Rohrich RJ. The nature of long-term fillers and the risk of complications. Dermatol Surg 2009;35 Suppl 2:1598-604.
83. Alhede M, Er Ö, Eickhardt S, et al. Bacterial biofilm formation and treatment in soft tissue fillers. Pathog Dis 2014;70:339-46.
84. Christensen LH. Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers. Dermatol Surg 2009;35 Suppl 2:1612-9.
85. Christensen L, Breiting V, Bjarnsholt T, et al. Bacterial infection as a likely cause of adverse reactions to polyacrylamide hydrogel fillers in cosmetic surgery. Clin Infect Dis 2013;56:1438-44.
86. Marusza W, Olszanski R, Sierdzinski J, et al. Treatment of late bacterial infections resulting from soft-tissue filler injections. Infect Drug Resist 2019;12:469-80.
87. Høiby N, Bjarnsholt T, Moser C, et al. ESCMID Study Group for Biofilms and Consulting External Expert Werner Zimmerli. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect 2015;21 Suppl 1:S1-25.
88. von Csiky-Sessoms SC, Gidumal SS, Marmur E, Lin G. Surgical management of a dermal filler-associated aseptic abscess. Dermatol Surg 2021;47:753-4.
89. Nygart JF, Nygart VA, Borggren M, Tvede M. Effect of prophylactic antibiotics on polyacrylamide gel safety in facial augmentation. J Drugs Dermatol 2014;13:571-3.
90. Ozturk CN, Li Y, Tung R, Parker L, Piliang MP, Zins JE. Complications following injection of soft-tissue fillers. Aesthet Surg J 2013;33:862-77.
91. Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces restylane-mediated cutaneous augmentation. Arch Facial Plast Surg 2005;7:231-7.
92. Zhang-Nunes S, Ryu C, Cahill K, et al. Prospective
93. Ryu C, Lu JE, Zhang-Nunes S. Response of twelve different hyaluronic acid gels to varying doses of recombinant human hyaluronidase. J Plast Reconstr Aesthet Surg 2021;74:881-9.
94. Reddy KK, Brauer JA, Anolik R, et al. Calcium hydroxylapatite nodule resolution after fractional carbon dioxide laser therapy. Arch Dermatol 2012;148:634-6.
95. Vrcek IM, Malouf P, Gilliland GD. A novel solution for superficially placed calcium hydroxylapatite (Radiesse) in the inferior eyelid. Orbit 2012;31:431-2.
96. Jung H. Hyaluronidase: an overview of its properties, applications, and side effects. Arch Plast Surg 2020;47:297-300.
97. Kim MS, Youn S, Na CH, Shin BS. Allergic reaction to hyaluronidase use after hyaluronic acid filler injection. J Cosmet Laser Ther 2015;17:283-5.
98. Mehta P, Ryu C, Park K, Kherani F, Zhang-Nunes S. Response of five different hyaluronic acid gels to varying doses of recombinant human hyaluronidase. J Plast Reconstr Aesthet Surg 2023;76:298-300.
99. De Boulle K, Glogau R, Kono T, et al. A review of the metabolism of 1,4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers. Dermatologic Surg 2013;39:1758-66.
100. Gold MH. Use of hyaluronic acid fillers for the treatment of the aging face. Clin Interv Aging 2007;2:369-76.
101. Ugradar S. Quantifying the digestion of cross-linked hyaluronic acid fillers with hyaluronidase. Dermatol Surg 2021;47:1233-6.
102. Heydenrych I, Kapoor KM, De Boulle K, et al. A 10-point plan for avoiding hyaluronic acid dermal filler-related complications during facial aesthetic procedures and algorithms for management. Clin Cosmet Investig Dermatol 2018;11:603-11.
103. Bailey SH, Cohen JL, Kenkel JM. Etiology, prevention, and treatment of dermal filler complications. Aesthet Surg J 2011;31:110-21.
104. Malik E, Dennison SR, Harris F, Phoenix DA. pH dependent antimicrobial peptides and proteins, their mechanisms of action and potential as therapeutic agents. Pharmaceuticals 2016;9:67.
105. Lafaille P, Benedetto A. Fillers: contraindications, side effects and precautions. J Cutan Aesthet Surg 2010;3:16-9.
106. Narins RS, Coleman WP 3rd, Glogau RG. Recommendations and treatment options for nodules and other filler complications. Dermatol Surg 2009;35 Suppl 2:1667-71.
107. Zein M, Tie-Shue R, Pirakitikulr N, Lee WW. Complications after cosmetic periocular filler: prevention and management. Plast Aesthet Res 2020;7:44.
108. Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg 2007;26:34-9.
109. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 2008;34 Suppl 1:S105-9.
110. Urdiales-Gálvez F, De Cabo-Francés FM, Bové I. Ultrasound patterns of different dermal filler materials used in aesthetics. J Cosmet Dermatol 2021;20:1541-8.
111. Arlette J, Velthuis PJ, Schelke LW. Ultrasound for soft tissue filler facial rejuvenation. J Cutan Med Surg 2021;25:456-7.
112. Mlosek RK, Skrzypek E, Skrzypek DM, Malinowska S. High-frequency ultrasound-based differentiation between nodular dermal filler deposits and foreign body granulomas. Skin Res Technol 2018;24:417-22.
113. Park KE, Mehta P, Tran C, Parikh AO, Zhou Q, Zhang-nunes S. A comparison of five point-of-care ultrasound devices for use in ophthalmology and facial aesthetics. Ultrasound 2023:online ahead of print.
114. Ginat DT, Schatz CJ. Imaging of facial fillers: additional insights. AJNR Am J Neuroradiol 2012;33:E140-1.
115. Mundada P, Kohler R, Boudabbous S, Toutous Trellu L, Platon A, Becker M. Injectable facial fillers: imaging features, complications, and diagnostic pitfalls at MRI and PET CT. Insights Imaging 2017;8:557-72.
116. Tal S, Maresky HS, Bryan T, et al. MRI in detecting facial cosmetic injectable fillers. Head Face Med 2016;12:27.
117. Master M. Hyaluronic acid filler longevity and localization: magnetic resonance imaging evidence. Plast Reconstr Surg 2021;147:50e-3e.
118. Kadouch JA, Tutein Nolthenius CJ, Kadouch DJ, van der Woude HJ, Karim RB, Hoekzema R. Complications after facial injections with permanent fillers: important limitations and considerations of MRI evaluation. Aesthet Surg J 2014;34:913-23.
119. Di Girolamo M, Mattei M, Signore A, Grippaudo FR. MRI in the evaluation of facial dermal fillers in normal and complicated cases. Eur Radiol 2015;25:1431-42.
120. Master M, Roberts S. Long-term MRI follow-up of hyaluronic acid dermal filler. Plast Reconstr Surg Glob Open 2022;10:e4252.
121. Savva D, Battineni G, Amenta F, Nittari G. Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. Int J Infect Dis 2021;113:233-5.
122. Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination-a case report. J Cosmet Dermatol 2021;20:2684-90.
123. Rowland-Warmann MJ. Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection-a case report. J Cosmet Dermatol 2021;20:1557-62.
124. Shome D, Doshi K, Vadera S, Kapoor R. Delayed hypersensitivity reaction to hyaluronic acid dermal filler post-COVID-19 viral infection. J Cosmet Dermatol 2021;20:1549-50.
125. Kalantari Y, Sadeghzadeh-Bazargan A, Aryanian Z, Hatami P, Goodarzi A. First reported case of delayed-type hypersensitivity reaction to non-hyaluronic acid Polycaprolactone dermal filler following COVID-19 vaccination: a case report and a review of the literature. Clin Case Rep 2022;10:e05343.
